Biosergen utvecklar nya behandlingar av invasiva svampinfektioner, ett område där endast en ny klass av svampdödande läkemedel har utvecklats på tre decennier. (presentationen görs på engelska)
Biosergen is a biotechnology company that employs the majority of its organisational and financials resources on the clinical development of BSG005. BSG005 is a potentially disruptive antifungal drug with blockbuster potential based on significant safety and potency advantages over competing antifungals, including Amphotericin B, in more than a decade of preclinical studies.
“Biosergen has now completed and will discuss the phase 1 clinical trial with it’s very positive outcome and is ready to move into phase II trials in patients with Invasive Fungal Infections.” biosergen.net/
@biosergen8485@biosergen8485
#biosergen #lifescience #aktien
Негізгі бет Biosergen AB (publ) på Investerarmötet 14 februari 2024
Пікірлер